These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 27379386

  • 1. Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis.
    Sakaida I, Terai S, Nakajima K, Shibasaki Y, Tachikawa S, Tsubouchi H.
    J Gastroenterol; 2017 Feb; 52(2):229-236. PubMed ID: 27379386
    [Abstract] [Full Text] [Related]

  • 2. Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan.
    Sakaida I, Nakajima K, Okita K, Hori M, Izumi T, Sakurai M, Shibasaki Y, Tachikawa S, Tsubouchi H, Oka H, Kobayashi H.
    J Gastroenterol; 2015 Oct; 50(10):1047-53. PubMed ID: 25689936
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinical Factors Predicting the Effect of Tolvaptan for Refractory Ascites in Patients with Decompensated Liver Cirrhosis.
    Chishina H, Hagiwara S, Nishida N, Ueshima K, Sakurai T, Ida H, Minami Y, Takita M, Kono M, Minami T, Iwanishi M, Umehara Y, Watanabe T, Komeda Y, Arizumi T, Kudo M.
    Dig Dis; 2016 Oct; 34(6):659-664. PubMed ID: 27750234
    [Abstract] [Full Text] [Related]

  • 7. Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis.
    Tajiri K, Tokimitsu Y, Ito H, Atarashi Y, Kawai K, Minemura M, Yasumura S, Takahara T, Shimizu Y, Sugiyama T.
    Dig Dis; 2018 Oct; 36(4):314-321. PubMed ID: 29852495
    [Abstract] [Full Text] [Related]

  • 8. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis.
    Okita K, Sakaida I, Okada M, Kaneko A, Chayama K, Kato M, Sata M, Yoshihara H, Ono N, Murawaki Y.
    J Gastroenterol; 2010 Sep; 45(9):979-87. PubMed ID: 20387081
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study).
    Sakaida I, Terai S, Kurosaki M, Okada M, Hirano T, Fukuta Y.
    J Gastroenterol; 2020 Aug; 55(8):800-810. PubMed ID: 32388692
    [Abstract] [Full Text] [Related]

  • 12. The pharmacokinetics and pharmacodynamics of tolvaptan in patients with liver cirrhosis with insufficient response to conventional diuretics: a multicentre, double-blind, parallel-group, phase III study.
    Sakaida I, Yanase M, Kobayashi Y, Yasutake T, Okada M, Okita K, ASCITES Clinical Pharmacology Group.
    J Int Med Res; 2012 Aug; 40(6):2381-93. PubMed ID: 23321196
    [Abstract] [Full Text] [Related]

  • 13. Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites.
    Goto A, Terai S, Nakamura M, Matsumoto M, Sakaida I.
    Clin J Gastroenterol; 2015 Feb; 8(1):47-51. PubMed ID: 25475138
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Serum Copeptin and Zinc-α2-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites.
    Shigefuku R, Iwasa M, Eguchi A, Tempaku M, Tamai Y, Suzuki T, Takei Y.
    Intern Med; 2021 Feb; 60(21):3359-3368. PubMed ID: 34719623
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia.
    Wang S, Zhang X, Han T, Xie W, Li Y, Ma H, Liebe R, Weng H, Ding HG.
    BMC Gastroenterol; 2018 Sep 04; 18(1):137. PubMed ID: 30180806
    [Abstract] [Full Text] [Related]

  • 18. Ratio of urine and blood urea nitrogen concentration predicts the response of tolvaptan in congestive heart failure.
    Shimizu K, Doi K, Imamura T, Noiri E, Yahagi N, Nangaku M, Kinugawa K.
    Nephrology (Carlton); 2015 Jun 04; 20(6):405-12. PubMed ID: 25619790
    [Abstract] [Full Text] [Related]

  • 19. The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan.
    Kogiso T, Kobayashi M, Yamamoto K, Ikarashi Y, Kodama K, Taniai M, Torii N, Hashimoto E, Tokushige K.
    Intern Med; 2017 Nov 15; 56(22):2993-3001. PubMed ID: 28943585
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma.
    Miyazaki M, Yada M, Tanaka K, Senjyu T, Goya T, Motomura K, Kohjima M, Kato M, Masumoto A, Kotoh K.
    World J Gastroenterol; 2017 Aug 07; 23(29):5379-5385. PubMed ID: 28839438
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.